Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7575475 | 0.89 | ALDH1A1 (0.70) | RAB9ANPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8468277 | 0.86 | KMT2A (0.65) | MAPTRAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL14266467 | 0.86 | KMT2A (0.77) | MAPTRAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL7102593 | 0.84 | MAPT (0.83) | MAPTRAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL21998673 | 0.84 | ALDH1A1 (0.67) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C9 | |
| SCHEMBL21998681 | 0.84 | ALDH1A1 (0.67) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C9 | |
| SCHEMBL21998663 | 0.84 | ALDH1A1 (0.67) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C9 | |
| SCHEMBL23932815 | 0.83 | KMT2A (0.73) | MAPTRAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL6689527 | 0.83 | KMT2A (0.73) | MAPTRAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL6408672 | 0.83 | KMT2A (0.73) | MAPTRAB9ASMN1; SMN2NPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-7417052-B2 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | SANKYO COMPANY, LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | MAPT 4844/4885RAB9A 1703/4885SMN1; SMN2 2719/4885 |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | JAK2, ABL1, CYP3A5 | MAPT 2539/4885RAB9A 4306/4885SMN1; SMN2 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.